The Experts below are selected from a list of 201 Experts worldwide ranked by ideXlab platform

D N De Simone - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacokinetic behavior of gadoteridol injection.
    Investigative radiology, 1992
    Co-Authors: S J Mclachlan, S Eaton, D N De Simone
    Abstract:

    To assess the safety and pharmacokinetics of gadoteridol injection (0.5 M) in 18 healthy male volunteers in a phase I clinical trial. Volunteers were assigned to one of six dosing groups: 0.05, 0.1, 0.15, 0.2, 0.25, and 0.3 mmol/kg gadoteridol (0.5 M), in an ascending dose study. Physical examination, vital signs, electrocardiogram, clinical laboratory tests, and serum and urine samples were obtained at selected time points before and after administration of gadoteridol. No significant changes in vital signs, physical examination, clinical laboratory values, or electrocardiogram, that were believed by the principal investigator to be related to the administration of the contrast agent, were observed. A single adverse event (transient hive) believed to be related to contrast agent administration was observed in one volunteer. Pharmacokinetic data show that the elimination Half-Life and the Distribution Half-Life were independent of the dose used. The mean Distribution Half-Life was 0.20 +/- 0.04 hours, the mean elimination Half-Life was 1.57 +/- 0.08 hours, and greater than 94% of the drug was excreted in the urine in 24 hours.

  • Pharmacokinetic behavior of gadoteridol injection.
    Investigative Radiology, 1992
    Co-Authors: S J Mclachlan, S Eaton, D N De Simone
    Abstract:

    Rationale and objectives To assess the safety and pharmacokinetics of gadoteridol injection (0.5 M) in 18 healthy male volunteers in a phase I clinical trial. Methods Volunteers were assigned to one of six dosing groups: 0.05, 0.1, 0.15, 0.2, 0.25, and 0.3 mmol/kg gadoteridol (0.5 M), in an ascending dose study. Physical examination, vital signs, electrocardiogram, clinical laboratory tests, and serum and urine samples were obtained at selected time points before and after administration of gadoteridol. Results and conclusions No significant changes in vital signs, physical examination, clinical laboratory values, or electrocardiogram, that were believed by the principal investigator to be related to the administration of the contrast agent, were observed. A single adverse event (transient hive) believed to be related to contrast agent administration was observed in one volunteer. Pharmacokinetic data show that the elimination Half-Life and the Distribution Half-Life were independent of the dose used. The mean Distribution Half-Life was 0.20 +/- 0.04 hours, the mean elimination Half-Life was 1.57 +/- 0.08 hours, and greater than 94% of the drug was excreted in the urine in 24 hours.

Tadayoshi Kosugi - One of the best experts on this subject based on the ideXlab platform.

  • Azelastine and suplatast shorten the Distribution Half-Life of IgE in rats.
    Mediators of inflammation, 2002
    Co-Authors: Kazuhiko Hanashiro, Yoshihiro Tokeshi, Toshiyuki Nakasone, Masanori Sunagawa, Mariko Nakamura, Tadayoshi Kosugi
    Abstract:

    We aim to clarify whether suplatast and azelastine (anti-allergic drugs) can shorten the Half-Life of immunoglobulin E (IgE) in the circulating blood. Thirty Wistar rats were divided into six groups. Distilled water or anti-allergic drugs were given orally for 6 days after the first sensitization. Two milligrams of monoclonal dinitrophenyl (DNP)-specific rat IgE was administered to the rats, which had been given suplatast or azelastine orally. The level of DNP-specific rat IgE in the serum was estimated by IgE-capture enzyme-linked immunosorbent assay, and the turnover of IgE was analyzed from its pharmacokinetic parameters. The elimination Half-Life of rat IgE was about 12 h irrespective of the sensitized state. The intercompartmental rate constants (Kct and Ktc) in the suplatast-administered or azelastine-administered group were larger than those of the distilled water-administered group under non-sensitized conditions. These findings suggested that the anti-allergic drugs used in the present study facilitated the excretion of IgE from the circulation in rats.

G. M. Antón-fos - One of the best experts on this subject based on the ideXlab platform.

  • Correlation of Pharmacological Properties of a Group of β‐Blocker Agents by Molecular Topology
    The Journal of pharmacy and pharmacology, 1995
    Co-Authors: F. J. García-march, R. A. Cercós-del-pozo, Facundo Pérez-giménez, J. Jaén-oltra, G. M. Antón-fos
    Abstract:

    The molecular connectivity method has been applied to the study of pharmacological properties, among which are found the angor treatment dose, alpha-Distribution Half-Life and intravenous LD50 in mouse, of a group of beta-blocker agents, verifying its application in the prediction of theoretic values for said pharmacological properties. To do this, the obtained multiple regression functions of the corresponding connectivity indices were used in relation with the experimental values of the properties, which are accompanied by the statistical parameters used in their selection criteria, as well as the corresponding random and cross-validation studies of said functions, which corroborate the good correlation of the selected equations.

S J Mclachlan - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacokinetic behavior of gadoteridol injection.
    Investigative radiology, 1992
    Co-Authors: S J Mclachlan, S Eaton, D N De Simone
    Abstract:

    To assess the safety and pharmacokinetics of gadoteridol injection (0.5 M) in 18 healthy male volunteers in a phase I clinical trial. Volunteers were assigned to one of six dosing groups: 0.05, 0.1, 0.15, 0.2, 0.25, and 0.3 mmol/kg gadoteridol (0.5 M), in an ascending dose study. Physical examination, vital signs, electrocardiogram, clinical laboratory tests, and serum and urine samples were obtained at selected time points before and after administration of gadoteridol. No significant changes in vital signs, physical examination, clinical laboratory values, or electrocardiogram, that were believed by the principal investigator to be related to the administration of the contrast agent, were observed. A single adverse event (transient hive) believed to be related to contrast agent administration was observed in one volunteer. Pharmacokinetic data show that the elimination Half-Life and the Distribution Half-Life were independent of the dose used. The mean Distribution Half-Life was 0.20 +/- 0.04 hours, the mean elimination Half-Life was 1.57 +/- 0.08 hours, and greater than 94% of the drug was excreted in the urine in 24 hours.

  • Pharmacokinetic behavior of gadoteridol injection.
    Investigative Radiology, 1992
    Co-Authors: S J Mclachlan, S Eaton, D N De Simone
    Abstract:

    Rationale and objectives To assess the safety and pharmacokinetics of gadoteridol injection (0.5 M) in 18 healthy male volunteers in a phase I clinical trial. Methods Volunteers were assigned to one of six dosing groups: 0.05, 0.1, 0.15, 0.2, 0.25, and 0.3 mmol/kg gadoteridol (0.5 M), in an ascending dose study. Physical examination, vital signs, electrocardiogram, clinical laboratory tests, and serum and urine samples were obtained at selected time points before and after administration of gadoteridol. Results and conclusions No significant changes in vital signs, physical examination, clinical laboratory values, or electrocardiogram, that were believed by the principal investigator to be related to the administration of the contrast agent, were observed. A single adverse event (transient hive) believed to be related to contrast agent administration was observed in one volunteer. Pharmacokinetic data show that the elimination Half-Life and the Distribution Half-Life were independent of the dose used. The mean Distribution Half-Life was 0.20 +/- 0.04 hours, the mean elimination Half-Life was 1.57 +/- 0.08 hours, and greater than 94% of the drug was excreted in the urine in 24 hours.

Jill A. Panetta - One of the best experts on this subject based on the ideXlab platform.

  • Tissue Distribution of LY231617, an Antioxidant with Neuroprotectant Activity, in the Rat
    Journal of pharmaceutical sciences, 1995
    Co-Authors: Marcus E. Brewster, Wesley R. Anderson, Kerry S. Estes, Nicholas Bodor, Emil Pop, Jill A. Panetta
    Abstract:

    The tissue Distribution of a butylated phenol antioxidant, LY231617, which has been shown to exert potent neuroprotection action was examined. Preliminary pharmacokinetic examination suggested that LY231617 was eliminated in a biphasic fashion after iv administration to the rat with a Distribution Half-Life of 5 min and an elimination Half-Life of close to 2.5 h. The volume of Distribution of the compound was large (7.4 L), consistent with its lipophilic structure. Dosing paradigms that have historically resulted in pharmacologically relevant activity were examined and were found to generate brain tissue levels of LY231617 of approximately 45 μg/g.